Summary & Overview
HCPCS M1197: Itch Severity Assessment, 3+ Point Improvement
HCPCS Level II code M1197 documents a clinically meaningful improvement in itch severity, defined as a reduction of 3 or more points from the initial assessment to a follow-up visit. As an outcome-focused code, M1197 enables clinicians and payers to track symptom change over time and supports value-based measurement of dermatologic or pruritus-related treatments. Nationally, consistent use of outcome codes like M1197 can inform quality programs and payer contract discussions that emphasize measurable patient improvement.
Key payers covered in the analysis include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. The publication reviews how these payers approach outcome documentation and the potential implications for coverage and quality reporting. Readers will find benchmarks for expected use when available, discussion of relevant policy contexts, and clinical context describing when the assessment is typically performed. The report also outlines common administrative considerations and the typical clinical settings for capture.
This summary equips billing professionals, clinicians, and policy analysts with a concise reference to the code’s clinical meaning, typical use cases, and areas where payer policies and reporting expectations may affect documentation and billing practices. Data not available in the input is noted where applicable in detailed sections.
Billing Code Overview
HCPCS Level II code M1197 describes an itch severity assessment where the patient’s follow-up score is reduced by 3 or more points compared with the initial (index) assessment score. This code captures a measurable improvement in itch severity between visits and is used to document change in symptom burden over time.
-
Service type: Symptom assessment / outcome measurement
-
Typical site of service: Outpatient clinic or ambulatory care setting where follow-up symptom assessment is performed, including dermatology or primary care follow-up visits.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult attending a dermatology or primary care follow-up visit to evaluate response to therapy for chronic pruritus (itch). At the index visit the clinician documents an itch severity assessment score (for example a Visual Analog Scale or Numerical Rating Scale) and initiates or adjusts therapy — topical emollients, topical corticosteroids, oral antihistamines, systemic immunomodulators, or referral for specialist tests. At the follow-up visit, usually 2–12 weeks later depending on therapy, the clinician repeats the same validated itch severity scale. This billing descriptor applies when the follow-up score is reduced by 3 or more points compared with the index assessment, demonstrating clinically meaningful improvement. Typical site of service is an outpatient clinic such as dermatology office, primary care office, or specialty dermatology infusion/therapy center. Typical patient scenario: a 58-year-old with chronic atopic dermatitis and baseline itch score 8/10 started on topical steroid and systemic antihistamine; at 6-week follow-up the patient reports itch score 4/10 (decrease ≥3 points) and the clinician documents the score comparison and treatment response in the medical record. Commonly involved staff include the clinician who performs assessment and documents the comparison, medical assistants who may record scores, and nursing staff who support treatment administration when applicable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when documentation supports additional work or complexity beyond typical documentation for the assessment visit. |